AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03033342
Drug: Oral single doses of placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of placebo to match MRX-4
Trial: NCT03033342
Drug: Oral multiple doses of placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo given twice daily for 10 days to match the oral MRX-4
Trial: NCT03322215
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral tablet 500 - 1,250 mg/m2 twice Daily, for 2 weeks followed by 1 week of rest.
Trial: NCT01910870
Drug: Metronomic Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg per os from day 1 to day 14 (total dose = 2100 mg) every 3 weeks
Trial: NCT01238978
Drug: Usual Care
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000514
Drug: chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02382848
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin-matched placebo pill
Trial: NCT00865085
Drug: CelexaTM 40 mg tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Forest Labs formulated products under fasting conditions
Trial: NCT01595581
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 weeks of testosterone administration beginning 2 weeks before ACL surgery
Trial: NCT01595581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 weeks of saline administration beginning 2 weeks before ACL surgery
Trial: NCT01713556
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00473603
Drug: lipid/heparin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to perform an i.v. lipid heparin infusion infusion for 4 h
Trial: NCT02426151
Drug: BEPO-A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEPO-A (Bioreactor manufacturing process)
Trial: NCT02426151
Drug: REPO-A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REPO-A (Roller bottle manufacturing process)
Trial: NCT03474081
Drug: FF/UMEC/VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single inhaler triple therapy of FF/UMEC/VI will be provided via ELLIPTA DPI. FF/UMEC/VI will be available as dry white powder with dosing strengths of 100/25/62.5 mcg per blister.
Trial: NCT03474081
Drug: Placebo to match FF/UMEC/VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching FF/UMEC/VI will be available as a dry white powder of lactose or magnesium stearate, administered via ELLIPTA DPI.
Trial: NCT02437786
Drug: GRAZAX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRAZAX
Trial: NCT00272116
Drug: Zinc and vitamin A single dose at enrollment
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day of elemental zinc as zinc gluconate to infants and 20 mg/day to older children
Trial: NCT00737594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules for oral administration
Trial: NCT01730404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02558400
Drug: PG324 Ophthalmic Solution 0.02%/0.005%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)
Trial: NCT04507165
Drug: opioid free anesthesia
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia induction: Dexmedetomidine 1µg/kg (intravenous infusion within 10min), propofol 1.5-2mg/kg (intravenous bolus), lidocaine 1.5-2mg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus), and 0.5% tetracaine 5ml for surface anesthesia of the throat.~Maintenance of anesthesia: Continuous infusion of propofol and dexmedetomidine \[0.4μg/(kg.h)\]. The infusion rate of propofol was adjusted according to bispectral index value. Cisatracurium besylate was given as needed. Flurbiprofen 50mg was given intravenously before the skin incision and suture respectively.~Remedy: If blood pressure rises (more than 30% of the mean arterial pressure after induction), and heart rate increases (more than 30% of heart rate after induction) during skin incision, lidocaine 1.5mg/kg will be given intravenously and then be continuously infused at a rate of 1.5mg/(kg.h).
Trial: NCT04507165
Drug: opioid based anesthesia
RxNorm normalized name: Opioid anesthetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia induction: Propofol 1.5-2mg/kg (intravenous bolus), sufentanil 0.3μg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus).~Maintenance of anesthesia: Continuous infusion of propofol and remifentanil. The infusion rate of propofol was adjusted according to BIS value. The infusion rate of remifentanil was 0.1-0.5µg/(kg.min) and adjusted according to the change of heart rate and blood pressure. Cisatracurium besylate was given as needed. Sufentanil 0.1μg/kg and flurbiprofen 50mg were given intravenously before the skin incision and suture respectively.
Trial: NCT00911573
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg IV every 12 hours up to 14 days
Trial: NCT00911573
Drug: Clindamycin (or Vancomycin if needed)
RxNorm normalized name: clindamycin Medicated Pad or Tape
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For clindamycin 10mg/kg (not to exceed 900mg) IV every 8 hours up to 14 days. For vancomycin 15mg/kg (not to exceed 2g/day and adjusted as needed for renal impairment) IV every 8 hours
Trial: NCT03159104
Drug: Tenoten for children
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral use.
Trial: NCT03159104
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral use.
Trial: NCT01076621
Drug: 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data collection of the use of 0.5 mg estradiol and 0.1 mg norethisterone acetate (NETA) in women in connection to a daily clinical practice.
Trial: NCT02530996
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the experimental days, patients reported to the laboratory after having consumed a standardized breakfast and oral BH4 (10mg/kg) or placebo five hours prior to their arrival. All measurements were taken at the same time of day to eliminate any diurnal effects. All participants abstained from alcohol, caffeine, and exercise for ≥12 hours prior to the study. Additionally, vasodilatory medications were discontinued 12 hours prior to study visit. In premenopausal women, measurements were performed during the early follicular phase of the menstrual cycle. All measurements were made under quiet, comfortable, ambient (\~22°C) laboratory conditions.
Trial: NCT02048371
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 days on and 7 days off
Trial: NCT02380898
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg ketorolac immediately before induction of anesthesia
Trial: NCT02380898
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL normal saline 0.9% immediately before induction of anesthesia
Trial: NCT02967939
Drug: Viread®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viread® 300mg tablet qd + placebo tablet matching to DA-2802 319mg.
Trial: NCT04030247
Drug: Plant Sterol
RxNorm normalized name: plant sterol complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a plant sterol supplement to take twice daily from their cardiologist/dietician in management of their moderate risk of cardiovascular disease.
Trial: NCT02234921
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single dose of cyclophosphamide, 300 mg/m2, will be administered intravenously 3 Days prior to the first vaccine.
Trial: NCT00240110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control arm
Trial: NCT03468972
Drug: Immunosuppressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At 3 months after randomization, patients in the corticosteroid arm who have persistent proteinuria of ≥ 1.0 g/g creatinine, or fast decline in eGFR ≥ 15% from the baseline value, will additionally receive cyclosphosphamide during the following 3 months. Patients who have substantial decreased amount of proteinuria \< 1.0 g/g creatinine at 3 months will continue protocol-based corticosteroids during the same period. At 6 months after randomization, patients who receive add-on cyclophosphamide will switch to azathioprine as a maintenance therapy and those who receive corticosteroids alone will discontinue the treatment and will be followed up during 24 months thereafter. Assessment of outcome will be done at 6 months and at 36 months.
Trial: NCT01722292
Drug: LY2940680
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01722292
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01417364
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected IM weekly throughout study
Trial: NCT00001724
Drug: Flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00411190
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen will be administered orally
Trial: NCT00411190
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen will be administered orally
Trial: NCT02239146
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of placebo administered intravenously (i.v.) to two subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
Trial: NCT02161276
Drug: TNTL capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were asked to taken drugs 3 times a day, with each time 3 grains
Trial: NCT02161276
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were asked to taken drugs 3 times a day, with each time 3 grains
Trial: NCT01013415
Drug: HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02270723
Drug: 5% Human Albumin  Behring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 5% Human Albumin during major surgery
Trial: NCT01151761
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2, PO
Trial: NCT01151761
Drug: 5FU
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m2
Trial: NCT02333890
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02406443
Drug: Sitaglitpin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days
Trial: NCT01181024
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching RO5303253 placebo, administered as single dose (Parts A + B) or multiple dose (Part C)
Trial: NCT04953871
Drug: TNF Inhibitor
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF inhibitors are widely used in patients with spondyloarthritis
Trial: NCT01181024
Drug: RO5303253
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohorts receiving single ascending doses
Trial: NCT01181024
Drug: RO5303253
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT01181024
Drug: RO5303253
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses
Trial: NCT01131741
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This group receives 3 mL of 1% lidocaine containing epinephrine IV during operation.
Trial: NCT00403780
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule placebo once or twice daily up to a total dose of 8 capsules(4 capsules twice daily) for a total of minimum 14 days and maximum 8 weeks. Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily.
Trial: NCT03689075
Drug: Envarsus Oral Product
RxNorm normalized name: Envarsus Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomised to receive either envarsus or to continue on an immediate release tacrolimus formulation
Trial: NCT03631277
Drug: Calcium Hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calcium hydroxide( Dycal ® Dentsply Caulk )was applied using calcium hydroxide applicator followed by glass ionomer and then composite resin as a final restoration
Trial: NCT04142151
Drug: Sanchitongshu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SanchiTongshu capsule produced by Chengdu Huashen Group Co., Ltd.
Trial: NCT04142151
Drug: placebo of Sanchitongshu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SanchiTongshu palcebo capsule contained dark brown muscovada sugar and the same inactive excipient (starch). Produced by Chengdu Huashen Group Co., Ltd.
Trial: NCT00913393
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV every 2 weeks for 22 weeks
Trial: NCT03037541
Drug: Placebo Cetaphil cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Cetaphil Cream will be used once daily for seven consecutive days
Trial: NCT00003358
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02603445
Drug: BCL201
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01407796
Drug: Endotoxin (E. coli O:113, Reference Endotoxin)
RxNorm normalized name: E.COLI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01407796
Drug: [18F](+/-)NOS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01685983
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number=5, form=tablet, route=oral. Patients will receive 1 tablet of prednisolone twice daily.
Trial: NCT00364533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed Dose Matching placebo for 3 days
Trial: NCT00331227
Drug: Isotonix OPC-3 (flavonoid supplement)
RxNorm normalized name: naphazoline hydrochloride 0.27 MG/ML / pheniramine maleate 3.15 MG/ML [Opcon-A]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01394887
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 850 mg gel capsules with starch (6.8 calories)as placebo
Trial: NCT03123614
Drug: Prednisolone Acetate 1% Oph Susp
RxNorm normalized name: PREDNISOLONE ACETATE 1% OPH SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04109833
Drug: ABT
RxNorm normalized name: Abtrim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: any antibiotic therapy in the first week of life
Trial: NCT03947970
Drug: [14C] CR845
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single dose of 230 mcg CR845 solution containing 100 microcuries \[14C\] CR845, administered via IV bolus (the total dose of CR845 will range from 1.7 to 3.1 mcg/kg)
Trial: NCT00973102
Drug: Premarin IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time dose of Premarin IV
Trial: NCT00973102
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time dose of placebo.
Trial: NCT03378648
Drug: CHF6366
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: CHF6366 (Part 1 - SAD) Single doses of CHF6366 at each period (for up to 3 periods per subject)~Drug: CHF6366 (Part 2 - MAD) Once daily doses of CHF6366 for 7 days~Drug: CHF6366 (Part 3) Single dose of CHF6366
Trial: NCT03378648
Drug: Placebo CHF6366
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo (Part 1 - SAD) Single doses of placebo matching CHF6366 at each period (for up to 3 periods per subjects)~Drug: Placebo (Part 2 - MAD) Once daily dose of placebo matching CHF6366 for 7 days~Drug: Placebo (Part 3) Single dose of placebo matching CHF6366
Trial: NCT00272688
Drug: Levodopa (drug), intraduodenal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00944463
Drug: Gemcitabine+simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine and simvastatin
Trial: NCT03926962
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visually matching placebo
Trial: NCT01439126
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, or 0.3 mg at Week 11; KAPVAY™ 0.1 mg, KAPVAY™ 0.2 mg, or placebo at Week 12; KAPVAY™ 0.1 mg or placebo at Week 13; placebo from Weeks 14-36
Trial: NCT03715192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT01290900
Drug: NXL104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Solution
Trial: NCT01290900
Drug: Placebo Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Saline
Trial: NCT04129710
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-hr infusion) on day 1
Trial: NCT04129710
Drug: PEGylated recombinant human granulocyte colony
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.
Trial: NCT02244151
Drug: Decapeptyl® diario
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decapeptyl® daily administration (Triptorelin acetate) and follicular puncture at 24, 30, 36 or 40 after administration.
Trial: NCT02244151
Drug: Decapeptyl® daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decapeptyl® daily OPU 36 hrs after GnRH administration
Trial: NCT00624416
Drug: Prednisolone synthetic cortisone and Isoproterenol together
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.
Trial: NCT00490022
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel for one month
Trial: NCT04615325
Drug: RO7303359
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO730359 will be administered as a single intravitreal injection.
Trial: NCT01638104
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once by 12 hour continuous intravenous infusion with D5W (USP)
Trial: NCT01869413
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.
Trial: NCT01355796
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of 7 % saline aerosolized twice a day for 2 weeks
Trial: NCT02871687
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg daily followed by potential increase to 40 mg simvastatin according to dose escalation procedure
Trial: NCT02871687
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg daily followed by potential increase to 80 mg pravastatin according to dose escalation procedure
Trial: NCT02973776
Drug: Dermoval®/Dermovate®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03447093
Drug: Propylthiouracil Pill
RxNorm normalized name: propylthiouracil Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who developed GD received propylthiouracil treatment
Trial: NCT01522404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in this intervention will receive inactive compound up to weeks 29 and will cross over to the other group
Trial: NCT05840692
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00287794
Drug: diazepam, melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of diazepam or such drugs may improve the sleep disturbance of patients with RA.
Trial: NCT02315508
Drug: AUT00063
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg orally, once a day, for 4 weeks
Trial: NCT02315508
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, once a day, for 4 weeks
Trial: NCT01669408
Drug: Cold crystalloid infusions, 0.9%NaCl or Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 1L cold crystalloid solution (4°C) over 15 minutes